Skip to main content

Biosimilars Expert Insights

First Report Managed Care
It seems like nearly all of my recent conversations with clients and other non-managed care parties center around the cost of specialty drugs. The rising cost of specialty medications, coupled with the increasing number of conditions specialty medications are being used to treat, have made deep…
Back to Top